AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 212 min read$ELV

Elevance Health Q3 2026: Revenue $50.4B, Adj. diluted EPS $6.99; FY guidance raised

Elevance Health reported Q3 2026 revenue of $50.4B, adjusted diluted EPS of $6.99. The company raised FY 2026 guidance for diluted EPS to at least $22.00 and adjusted diluted EPS to at least $29.00, citing improved performance and stronger Carelon results. Operating cash flow guidance was also increased to at least $6.5B.

Original reporting
tradingview.com
Published Oct 21, 2026, 10:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Elevance Health Q3 2026: Revenue $50.4B, Adj. diluted EPS $6.99; FY guidance raised — source image
Source · tradingview.com
Decision brief

The 30-second read

$ELVBullishHigh
01

Why it matters

The guidance lift suggests improved profitability and cash generation, likely supporting a price rally.

02

Market read

First‑report earnings and guidance update for a large‑cap insurer; actionable for traders.

03

What to watch

Potential headwinds from Medicaid enrollment declines and membership attrition.

Relevance 9/10Novelty 9/10Timing: today

Background

Elevance Health reported Q3 2026 results with modest revenue growth and announced raised FY guidance.

Company-level read

Ticker impact

$ELVBullishHigh confidence
Context

Elevance Health raised FY 2026 adjusted diluted EPS guidance to at least $29.00 and operating cash flow guidance to at least $6.5 billion.

Expected impact

likely upward pressure as investors price in higher earnings and cash flow expectations

Evidence & confidence

Guidance upgrades are material for a large‑cap health insurer and typically trigger buying.

Market effects

Sector

Higher guidance may lift peer health‑benefits insurers and related biotech payers.

Regional

U.S. health‑insurance sector could see modest gains.

Global

Limited to U.S. markets; no immediate global ripple.

Counterpoint

What could challenge this read

If guidance is already priced in, the stock could face a short‑term pullback.

Key entities

  • company
    Elevance Health

    U.S. health‑benefits insurer (ticker ELV).

Read at source← All news

StoryElevance Health posts Q3 2026 earnings beat and lifts FY 2026 EPS and cash‑flow guidance

Also covered by

4 outlets

Related articles

OCT 21
$TSLAMed

Nasdaq futures lead gains as SpaceX, Super Micro results lift AI trade

Nasdaq futures rose on Wednesday, led by gains in SpaceX (up 7.2%) and Super Micro (up 10.9%) after their earnings reports. SpaceX posted its first profit as a public company, while Super Micro exceeded revenue and profit margin estimates. Tesla (up 1.4%) also gained after Elon Musk suggested a potential merger with SpaceX. Netflix fell 6.6% after issuing a weaker-than-expected forecast. Other AI-related stocks and chipmakers also saw gains.

kitco.com3 min
OCT 21
$ELVMedAI 8/10

Elevance Health Reports $1.3 Billion Profit As Insurer’s Costs Ease

Elevance Health reported Q3 net income of $1.36B, up 15% YoY. Costs eased in Medicare and ACA plans, improving the benefit expense ratio. The company raised its full-year EPS outlook to $22.00 from $20.10, citing continued momentum. Elevance is the second-largest U.S. health insurer, operating Anthem Blue Cross Blue Shield plans and Medicaid services.

finance.yahoo.com2 min